S

Spyre Therapeutics
D

SYRE

40.990
USD
0.95
(2.37%)
مغلق
حجم التداول
29,332
الربح لكل سهم
-5
العائد الربحي
-
P/E
-21
حجم السوق
3,219,361,322
المقالات

العنوان: Spyre Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting 47, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.